<DOC>
	<DOCNO>NCT00016445</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effect growth hormone height , height velocity , body weight , lean body mass patient cystic fibrosis . II . Determine effect growth hormone pulmonary function patient . III . Determine impact drug quality life patient . IV . Determine clinical response drug sustain patient .</brief_summary>
	<brief_title>Phase II Study Growth Hormone Children With Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . Arm I : Patients receive growth hormone subcutaneously ( SC ) daily 1 year first year . Arm II : Patients receive growth hormone SC daily 1 year second year . Quality life assess baseline every 6 month 2 year .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis prepubertal cystic fibrosis No colonization Burkholderia cepacia Prior/Concurrent Therapy No prior concurrent insulin requirement Patient Characteristics Hematopoietic : No hematologic disease Hepatic : No liver disease Renal : No kidney disease Pulmonary : Must able perform pulmonary function test Other : No history diabetes Must le 25 % normal height and/or weight age sex</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>quality life</keyword>
	<keyword>rare disease</keyword>
</DOC>